But the specifics depend on your formulation type
Eli Lilly and Company, the maker of Zepbound (tirzepatide) and Foundayo (orforglipron), has announced positive topline results from a phase 3 clinical trial evaluating the efficacy and safety of retatrutide, an investigational, first-in-class GIP, GLP-1, and glucagon triple hormone receptor agonist, in adults with obesity or overweight and at least one weight-related comorbidity and without diabetes
The massive weight-loss numbers you see in commercials, 15% to 20% body-weight loss, come from high therapeutic doses in controlled clinical trials
FA: Writing original draft
It acts on GLP-1, GIP, and glucagon receptors, which makes it more comprehensive in its approach compared to Semaglutide, which focuses only on GLP-1